Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study

Table 6 **Correlation between trough concentration of total drug* and change in laboratory parameters**

Laboratory parameter^†	Pearson correlation coefficient (R)^‡
Laboratory parameter^†	C3D1 (n = 29)	C5D1 (n = 18)
Absolute neutrophil count	0.15	-0.64
Leukocyte count	0.20	-0.79
Lymphocyte count	0.12	-0.21
Thrombocyte count	-0.33	-0.40
Systolic blood pressure	0.18	0.68
Diastolic blood pressure	0.06	0.51
Ejection fraction	-0.61	-0.21

Abbreviations: C cycle, D day.
*Sunitinib + SU12662.
^†Based on percent change from baseline.
^‡Weak correlation, |R| <0.50; moderate correlation, 0.50 ≤ |R| < 0.75; strong correlation, |R| ≥ 0.75.

ISSN: 1471-2407